Last reviewed 2026-04-22 · How we verify

Triamcinolone acetonide-Ketorolac-Ropivacaine

Triamcinolone acetonide-Ketorolac-Ropivacaine is a Combination injection (corticosteroid + NSAID + local anesthetic) Small molecule drug developed by United Health Services Hospitals, Inc.. It is currently FDA-approved for Intra-articular or soft tissue injection for pain and inflammation associated with musculoskeletal conditions.

This combination injection delivers a corticosteroid (triamcinolone acetonide) to reduce inflammation, a nonsteroidal anti-inflammatory drug (ketorolac) to inhibit prostaglandin synthesis and pain, and a local anesthetic (ropivacaine) to block nerve conduction.

This combination injection delivers a corticosteroid (triamcinolone acetonide) to reduce inflammation, a nonsteroidal anti-inflammatory drug (ketorolac) to inhibit prostaglandin synthesis and pain, and a local anesthetic (ropivacaine) to block nerve conduction. Used for Intra-articular or soft tissue injection for pain and inflammation associated with musculoskeletal conditions.

At a glance

Mechanism of action

Triamcinolone acetonide suppresses inflammatory responses by binding glucocorticoid receptors. Ketorolac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin-mediated inflammation and pain. Ropivacaine blocks sodium channels in nerve fibers to provide local anesthesia. Together, these agents provide multi-modal anti-inflammatory and analgesic effects at the injection site.

Approved indications

• Intra-articular or soft tissue injection for pain and inflammation associated with musculoskeletal conditions

Common side effects

• Local injection site reactions (pain, swelling, erythema)
• Temporary numbness or paresthesia from local anesthetic
• Systemic corticosteroid effects (with repeated use)
• Gastrointestinal effects from ketorolac

Key clinical trials

• Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (PHASE2, PHASE3)
• Effects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation (PHASE4)
• Triamcinolone Ketorolac (TriKe) Knee Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Triamcinolone acetonide-Ketorolac-Ropivacaine CI brief — competitive landscape report
• Triamcinolone acetonide-Ketorolac-Ropivacaine updates RSS · CI watch RSS
• United Health Services Hospitals, Inc. portfolio CI

Frequently asked questions about Triamcinolone acetonide-Ketorolac-Ropivacaine

Related

• Drug class: All Combination injection (corticosteroid + NSAID + local anesthetic) drugs
• Target: All drugs targeting Glucocorticoid receptor (triamcinolone); COX-1/COX-2 (ketorolac); voltage-gated sodium channels (ropivacaine)
• Manufacturer: United Health Services Hospitals, Inc. — full pipeline
• Therapeutic area: All drugs in Pain management, Orthopedics, Rheumatology
• Indication: Drugs for Intra-articular or soft tissue injection for pain and inflammation associated with musculoskeletal conditions
• Compare: Triamcinolone acetonide-Ketorolac-Ropivacaine vs similar drugs
• Pricing: Triamcinolone acetonide-Ketorolac-Ropivacaine cost, discount & access